BHF

BHF is no longer a fundamentals story — it is a merger-arbitrage situation. The 10-K explicitly states that on November 6, 2025 BHF signed a Merger Agreement to be acquired by Aquarian Parent, that stockholders adopted the agreement at the February 12, 2026 special meeting, and that the HSR waiting period has expired. What remains is regulatory approval from insurance regulators in Delaware, New York and Massachusetts, plus FINRA Rule 1017 change-of-control approval for Brighthouse Securities. Management expects close in 2026. The current $63.09 price almost certainly reflects a discount to the announced deal consideration, so the trade here is spread-to-close, not multiple expansion.

The underlying numbers are mixed and would not, on their own, justify aggressive accumulation. FY2025 revenue of $6.77B (+43.2% YoY) and diluted EPS of $5.71 look strong, but the 5-year history is whipsaw — net income swung from $3.88B (2022) to -$1.11B (2023) to $388M (2024) to $433M (2025) — which is the signature volatility of a variable-annuity book reacting to hedging marks and the annual actuarial assumption review (AAR) the MD&A flags. Liabilities/equity of 34.7x and a still-negative retained earnings balance of -$686M underscore that this is a thin-equity, capital-markets-sensitive insurer; ROE of just 6.4% on a 11x P/E and 0.5x P/S looks 'cheap' but is the standard discount the market applies to this business model.